X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

4WARD Phase 3 chronic neutropenia trial in full swing;
full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026